Forest Laboratories, Inc. to Host Analyst Meeting to Review the Company’s Late-Stage Product Development Pipeline

Forest Laboratories, Inc. (NYSE: FRX), an international manufacturer and marketer of pharmaceutical products, today announced that it will host an analysts meeting on Thursday, January 7, 2010 to review its late-stage product development pipeline. The meeting will feature product and therapeutic area presentations by senior leadership from the Forest Research Institute, Inc., the Company’s research and development arm, and senior corporate executives, with emphasis placed on the Company’s late-stage product opportunities. The meeting will be webcast live on the investor relations section of the Forest Laboratories website at www.frx.com.

To access the webcast, please log on to the Company’s website at www.frx.com, click on the “Webcast” link and follow the prompts for registration and access. The live webcast will begin at 8:30 a.m. EST and end at approximately 12:30 p.m. A replay of the webcast will be available from approximately 3:00 p.m. EST on January 7, 2010.

About Forest Laboratories

Forest Laboratories (NYSE: FRX) is a U.S.-based pharmaceutical company with a long track record of building partnerships and developing and marketing products that make a positive difference in people’s lives. In addition to its well-established franchises in therapeutic areas of the central nervous and cardiovascular systems, Forest’s current pipeline includes product candidates in all stages of development and across a wide range of therapeutic areas. The company is headquartered in New York, NY. To learn more about Forest Laboratories, visit www.frx.com.

Except for the historical information contained herein, this release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including the difficulty of predicting FDA approvals, the acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, the timely development and launch of new products, and the risk factors listed from time to time in Forest Laboratories’ Annual Report on Form 10-K, Quarterly Report on Form 10-Q, and any subsequent SEC filings.

Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From May 2024 to Jun 2024